-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compared with small molecule drug therapy, ADC has stronger specificity and fewer side effects, and compared with antibody drug, ADC has more prominent tumor killing effect
.
In recent years, domestic antibody-drug conjugate (ADC) drug research and development has been hot, and it has become a key direction for the layout of global innovative pharmaceutical companies.
The industry expects that it may usher in a new peak in 3-5 years
.
The market development space for ADC drugs is very considerable
.
According to data, the global ADC market is expected to reach $12.
9 billion by 2024
.
Among them, the number of ADC product research and development in China is mostly, and the market is expected to reach 7.
4 billion yuan
.
Currently, under the background that ADC drugs have become a hot spot in the industry, this field is continuing to attract R&D investment
.
It is reported that Yilian Biological recently announced the completion of a $70 million Series B financing
.
This round of financing was jointly led by LYFE Capital (Zhouling Capital) and Qiming Venture Capital, and followed by Legend Capital, Zhengxingu Capital and Honghui Fund (HLC)
.
The funds raised this time are mainly used for the clinical trial development of the company's next-generation ADC product pipeline and the early development of new conjugated drugs
.
According to the data, Yilian Bio was established in 2020.
Its founding team consists of a group of experts who are good at small molecule toxin-linker research and development, have expertise in antibody macromolecular drugs, do CMC technology, and have rich experience in research and development and management.
Professional management personnel
.
The company focuses on the development of drug conjugates with international competitiveness.
The company has established a drug conjugate technology platform with independent intellectual property rights, guided by unmet clinical needs, while promoting the simultaneous development of clinical research at home and abroad, and establishing complementary models with domestic and foreign partners.
Collaborate to serve patients around the world
.
At present, the first project of Yilian Bio has submitted a formal clinical application to the FDA this month, and clinical trials will be carried out simultaneously in China and the United States this year
.
Another 1 project is in the preclinical candidate compound (PCC) stage, 2 projects are in the process of humanized antibody construction, and 1 project is initiating immunization
.
At the same time, the company has reached project cooperation with a number of companies to jointly develop a new generation of antibody conjugated drugs
.
It is understood that within two months of early 2021, Yilian Bio has successively completed the A1 round of financing with a total of 350 million yuan led by Xingze Capital, and the investment jointly led by Zhengxingu Capital and Qiming Venture Capital.
A2 round financing for further additional investment by Xingze Capital
.
Qiming Ventures is still involved in this round of B round financing.
The institution said that it is optimistic about the advantages of Yilian Bio in the international competition in the field of conjugated drugs
.
He believes that the Yilian team has a clear development strategy, solid technical accumulation and efficient execution capabilities.
The past year has witnessed the gradual growth of Yilian Bio into an internationally competitive coupling technology platform-based Biotech company.
Bringing health and well-being to patients in China and around the world
.
At present, 14 ADC drugs have been approved for marketing in the world.
In the domestic market, many pharmaceutical companies, including Rongchang Bio, Lepu Bio, and Toyo Pharmaceutical, already have more ADC drug layouts and have entered the late clinical stage
.
Among them, Vidicitumab of Rongchang Bio has been approved for marketing in June 2021, becoming the first domestic ADC drug to be marketed in China
.
In addition, companies such as Genting Xinyao, Qilu Pharmaceutical, Lepu Bio, and Innovent Bio have also competed to deploy ADC drug pipelines through authorized introduction
.
It is foreseeable that with the addition of capital, domestic ADC drug research and development will be more active
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, domestic antibody-drug conjugate (ADC) drug research and development has been hot, and it has become a key direction for the layout of global innovative pharmaceutical companies.
The industry expects that it may usher in a new peak in 3-5 years
.
The market development space for ADC drugs is very considerable
.
According to data, the global ADC market is expected to reach $12.
9 billion by 2024
.
Among them, the number of ADC product research and development in China is mostly, and the market is expected to reach 7.
4 billion yuan
.
Currently, under the background that ADC drugs have become a hot spot in the industry, this field is continuing to attract R&D investment
.
It is reported that Yilian Biological recently announced the completion of a $70 million Series B financing
.
This round of financing was jointly led by LYFE Capital (Zhouling Capital) and Qiming Venture Capital, and followed by Legend Capital, Zhengxingu Capital and Honghui Fund (HLC)
.
The funds raised this time are mainly used for the clinical trial development of the company's next-generation ADC product pipeline and the early development of new conjugated drugs
.
According to the data, Yilian Bio was established in 2020.
Its founding team consists of a group of experts who are good at small molecule toxin-linker research and development, have expertise in antibody macromolecular drugs, do CMC technology, and have rich experience in research and development and management.
Professional management personnel
.
The company focuses on the development of drug conjugates with international competitiveness.
The company has established a drug conjugate technology platform with independent intellectual property rights, guided by unmet clinical needs, while promoting the simultaneous development of clinical research at home and abroad, and establishing complementary models with domestic and foreign partners.
Collaborate to serve patients around the world
.
At present, the first project of Yilian Bio has submitted a formal clinical application to the FDA this month, and clinical trials will be carried out simultaneously in China and the United States this year
.
Another 1 project is in the preclinical candidate compound (PCC) stage, 2 projects are in the process of humanized antibody construction, and 1 project is initiating immunization
.
At the same time, the company has reached project cooperation with a number of companies to jointly develop a new generation of antibody conjugated drugs
.
It is understood that within two months of early 2021, Yilian Bio has successively completed the A1 round of financing with a total of 350 million yuan led by Xingze Capital, and the investment jointly led by Zhengxingu Capital and Qiming Venture Capital.
A2 round financing for further additional investment by Xingze Capital
.
Qiming Ventures is still involved in this round of B round financing.
The institution said that it is optimistic about the advantages of Yilian Bio in the international competition in the field of conjugated drugs
.
He believes that the Yilian team has a clear development strategy, solid technical accumulation and efficient execution capabilities.
The past year has witnessed the gradual growth of Yilian Bio into an internationally competitive coupling technology platform-based Biotech company.
Bringing health and well-being to patients in China and around the world
.
At present, 14 ADC drugs have been approved for marketing in the world.
In the domestic market, many pharmaceutical companies, including Rongchang Bio, Lepu Bio, and Toyo Pharmaceutical, already have more ADC drug layouts and have entered the late clinical stage
.
Among them, Vidicitumab of Rongchang Bio has been approved for marketing in June 2021, becoming the first domestic ADC drug to be marketed in China
.
In addition, companies such as Genting Xinyao, Qilu Pharmaceutical, Lepu Bio, and Innovent Bio have also competed to deploy ADC drug pipelines through authorized introduction
.
It is foreseeable that with the addition of capital, domestic ADC drug research and development will be more active
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
